In summary, MCAD over-expressing BMDMs significantly inhibited tumor growth in the 4T1 breast cancer mouse model, indicating that the anti-tumorigenic role of MCAD might be valuable in the development of novel anti-cancer immunotherapies. This evidence concerns the gene ACADM and breast carcinoma.